Clinical trial
Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus
NCT00005924 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00005924 |
|---|---|
| Title | Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus |
| Official title | Persistence of Epstein-Barr Virus in Vivo |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Study type | Observational |
| Conditions | Epstein Barr Virus Infection, Healthy |
| Enrollment | 41 |
| Start date | Jun 23, 2000 |
| Completion | Feb 2, 2010 |
| First posted | Jun 26, 2000 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: